secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001104659-25-013509
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Q1: GAAP EPS $0.72 (fair value gains), adj EPS -$0.89; BLA resubmission on track
--------------------------------------------------------------------------------

- GAAP net income $17.4M ($0.72/sh) vs net loss $11.2M; adj net loss $21.6M ($0.89/sh) vs $10.1M ($0.78 loss) prior year.
- BLA resubmission for ONS-5010 (bevacizumab-vikg) targeted for Q1 CY2025; potential FDA approval in Q3 CY2025.
- First commercial launches of LYTENAVA in Germany and UK planned for Q2 CY2025; collaboration with Cencora announced.
- NORSE EIGHT trial missed primary non-inferiority endpoint at week 8; 12-week analysis met non-inferiority margin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/0001104659-25-013509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-013509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer